Generic Name and Formulations:
Tretinoin 0.025%; crm; gel.
Indications for AVITA:
Apply sparingly to cleansed and completely dry skin once daily at bedtime. If irritation develops, may reduce the dosing frequency.
Not for use in eczema or on sunburned skin. Minimize exposure to sun, UV light, weather extremes. Avoid eyes, mouth, angles of nose, mucous membranes. Pregnancy (Cat.C): not recommended. Nursing mothers.
Allow effects of benzoyl peroxide, sulfur, resorcinol, salicylic acid, other topical acne agents to subside before applying. Avoid keratolytics, abrasives, astringents, drying agents, high-alcohol content topical products, spices, lime.
Apparent exacerbation of symptoms, local skin reactions (including erythema, edema, blistering, crusting), transient pigmentation changes, stinging on application, dry skin.
Crm, gel—20g, 45g
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|